

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10530696
	Filing Date		2005-04-08
	First Named Inventor	Ozaki et al.	
	Art Unit	1643	
	Examiner Name	Anne Gussow	
Attorney Docket Number		14875-0141US1	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	JP10508868	JP		1998-09-02	UCKUN et al.		<input type="checkbox"/>
	2	JP2005529616	JP		2005-10-06	DEVERAUX et al.		<input type="checkbox"/>
	3	WO02028894	WO		2002-04-11	KOMATANI et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10530696
Filing Date	2005-04-08
First Named Inventor	Ozaki et al.
Art Unit	1643
Examiner Name	Anne Gussow
Attorney Docket Number	14875-0141US1

4	WO2005004912	WO		2005-01-20	NAKAMURA et al.	<input type="checkbox"/>
5	WO2008007755	WO		2008-01-17	KIMURA et al.	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	FISK et al., "Increased sensitivity of Adriamycin-selected Tumor Lines to CTL-mediated Lysis Results in Enhanced Drug Sensitivity," Cancer Res., 58:4790-4793 (1998)	<input type="checkbox"/>
	2	JALILI et al., "Multi-Drug Resistant Leukemic Cells Highly Express HLA Class I Molecules and Single-Chain Fv Diabody Specific to HLA-A Overcomes Drug Resistance in These Cells," Blood (ASH Annual Meeting Abstracts), 118 (11):701a-702a (#2376) (2007)	<input type="checkbox"/>
	3	MELGUISO et al., "Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells," Neoplasma, 50(2):91-96 (2003)	<input type="checkbox"/>
	4	OZAKI et al., "Induction of myeloma cell death by a recombinant HLA class I-specific single-chain Fv diabody," Dai 65 Nihon Ketsueki Gakkai, Dai 45 kai Nihon Ketsueki Gakkai Soka, Osaka (August 28-31, 2003)	<input checked="" type="checkbox"/>
	5	OZAKI et al., "A recombinant HLA class I-specific single chain Fv diabody induces cell death in human lymphoid malignancies," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003)	<input type="checkbox"/>
	6	PRADOS et al., "Induction of drug resistance in embryonal rhabdomyosarcoma treated with conventional chemotherapy is associated with HLA class I increase," Neoplasma, 53(3):226-231 (2006)	<input type="checkbox"/>
	7	SEKIMOTO et al., "Eradication of human myeloma cells by a recombinant HLA class I-specific single chain Fv diabody," 45th Annual Meeting of the American Society of Hematology, San Diego, CA, USA (December 6-9, 2003)	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10530696
Filing Date	2005-04-08
First Named Inventor	Ozaki et al.
Art Unit	1643
Examiner Name	Anne Gussow
Attorney Docket Number	14875-0141US1

8	SONNEVELD, "Multidrug resistance in haematological malignancies," J. Intern. Med., 247:521-534 (2000)	<input type="checkbox"/>
9	TSUKAKOSHI, New Pharmacology, 3rd revised edition, Nankodo Co., Ltd., 557-568 (1997)	<input type="checkbox"/>
10	JAPANESE PATENT OFFICE, International Search Report for App. Ser. No. PCT/JP2008/054443, dated May 27, 2008, 7 pages	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.